Vir Biotechnology, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Vir Biotechnology, Inc. (VIR), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are VIR insiders buying or selling?
In the last 12 months, Vir Biotechnology, Inc. insiders reported 0 open-market purchases ($0) and 33 sales ($13.0M) — net selling of $13.0M. Since October 2019, Trabud has recorded 283 Form 4 filings for VIR: 11 buys ($139.2M) and 272 sells ($250.0M).
Source: SEC EDGAR Form 4
What stands out
- No Vir Biotechnology, Inc. insider made an open-market purchase in the last 12 months; the 33 reported open-market sales totaled $13.0M.
Key Statistics (October 2019 – Jun 2, 2026)
Total Form 4 filings
283
SEC EDGAR
Insider filers
26
Insider buys (11)
$139.2M
Insider sells (272)
$250.0M
Insider sentiment
Net sellingNet insider flow of $110.7M in net selling since October 2019, and $13.0M in net selling over the last 12 months.
Recent VIR insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 2, 2026 | Janet Napolitano | Director | Sale | 3.2K | $9.45 | $30.2K | SEC ↗ |
| Jun 2, 2026 | Brent Sabatini | SVP, Chief Accounting Officer | Sale | 379 | $9.45 | $3.6K | SEC ↗ |
| May 4, 2026 | Vicki L Sato | Director | Sale | 22.0K | $10.05 | $221.0K | SEC ↗ |
| Apr 7, 2026 | Backer Marianne De | President and CEO | Sale | 72.6K | $9.16 | $664.4K | SEC ↗ |
| Apr 2, 2026 | Vicki L Sato | Director | Sale | 22.0K | $9.07 | $199.6K | SEC ↗ |
| Mar 24, 2026 | Brent Sabatini | SVP, Chief Accounting Officer | Sale | 7.7K | $9.12 | $70.3K | SEC ↗ |
| Mar 3, 2026 | Vicki L Sato | Director | Sale | 22.0K | $9.51 | $209.2K | SEC ↗ |
| Feb 26, 2026 | Vicki L Sato | Director | Sale | 42.4K | $9.75 | $413.4K | SEC ↗ |
| Feb 26, 2026 | Brent Sabatini | SVP, Chief Accounting Officer | Sale | 1.4K | $9.53 | $13.6K | SEC ↗ |
| Feb 26, 2026 | Jason O'Byrne | EVP & Chief Financial Officer | Sale | 1.6K | $9.53 | $15.6K | SEC ↗ |
| Feb 26, 2026 | Mark Eisner | EVP and Chief Medical Officer | Sale | 3.5K | $9.69 | $34.0K | SEC ↗ |
| Feb 26, 2026 | Verneuil Vanina de | EVP, General Counsel, Corp Sec | Sale | 16.8K | $9.77 | $164.2K | SEC ↗ |
| Feb 26, 2026 | Backer Marianne De | Chief Executive Officer | Sale | 14.8K | $9.53 | $140.7K | SEC ↗ |
| Feb 25, 2026 | Brent Sabatini | SVP, Chief Accounting Officer | Sale | 1.8K | $7.45 | $13.6K | SEC ↗ |
| Feb 25, 2026 | Jason O'Byrne | EVP & Chief Financial Officer | Sale | 2.1K | $7.45 | $15.6K | SEC ↗ |
| Feb 25, 2026 | Mark Eisner | EVP and Chief Medical Officer | Sale | 2.1K | $7.45 | $15.6K | SEC ↗ |
| Feb 25, 2026 | Verneuil Vanina de | EVP, General Counsel, Corp Sec | Sale | 4.4K | $7.45 | $33.1K | SEC ↗ |
| Feb 25, 2026 | Backer Marianne De | Chief Executive Officer | Sale | 19.0K | $7.45 | $141.9K | SEC ↗ |
| Feb 18, 2026 | Brent Sabatini | SVP, Chief Accounting Officer | Sale | 1.5K | $7.79 | $11.9K | SEC ↗ |
| Feb 3, 2026 | Vicki L Sato | Director | Sale | 22.0K | $7.71 | $169.7K | SEC ↗ |
| Jan 5, 2026 | Vicki L Sato | Director | Sale | 22.0K | $5.93 | $130.4K | SEC ↗ |
| Dec 3, 2025 | SVF Endurance (Cayman) Ltd | 10% Owner | Sale | 191.9K | $5.98 | $1.1M | SEC ↗ |
| Dec 3, 2025 | Vicki L Sato | Director | Sale | 22.0K | $6.00 | $132.1K | SEC ↗ |
| Dec 1, 2025 | SVF Endurance (Cayman) Ltd | 10% Owner | Sale | 189.4K | $6.41 | $1.2M | SEC ↗ |
| Nov 26, 2025 | SVF Endurance (Cayman) Ltd | 10% Owner | Sale | 463.8K | $6.27 | $2.9M | SEC ↗ |
Showing the 25 most recent of 283 Form 4 filings for Vir Biotechnology, Inc..
Most active VIR insiders
- SVF Endurance (Cayman) Ltd57 filings
- Herbert Virgin56 filings
- Phillip Pang37 filings
- Vicki L Sato36 filings
- Jay Parrish12 filings
Ask anything about VIR insider activity
Use Trabud's AI agent to query Vir Biotechnology, Inc.'s Form 4 history in plain English — "Show me VIR CEO purchases this year" or compare it against any other ticker.
Open the AI agentVIR insider trading FAQ
Are Vir Biotechnology, Inc. insiders buying or selling?
In the last 12 months, Vir Biotechnology, Inc. insiders reported 0 open-market purchases ($0) and 33 sales ($13.0M) — net selling of $13.0M. Since October 2019, Trabud has recorded 283 Form 4 filings for VIR: 11 buys ($139.2M) and 272 sells ($250.0M). Over the full record that is net selling of $110.7M.
How many insiders trade VIR stock?
26 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Vir Biotechnology, Inc.. The most recent filing was accepted on Jun 2, 2026.
Where does Trabud get VIR insider trading data?
All VIR insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.